65515-32-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Pyridinecarboxylic acid, 6-chloro-2-methoxy-, methyl ester is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure allows for the development of new therapeutic agents with potential applications in treating a range of medical conditions.
Used in Agrochemical Production:
In the agrochemical sector, 3-Pyridinecarboxylic acid, 6-chloro-2-methoxy-, methyl ester serves as an essential component in the creation of pesticides and other crop protection products. Its chemical properties make it suitable for the development of effective and targeted agrochemicals that can protect crops from pests and diseases.
Used in Research and Development:
3-Pyridinecarboxylic acid, 6-chloro-2-methoxy-, methyl ester is also utilized in research and development settings. Its unique structure and reactivity make it a valuable tool for exploring new chemical reactions and synthesizing novel compounds with potential applications in various fields.
Used in Fine Chemicals Production:
As an intermediate in the production of fine chemicals, 3-Pyridinecarboxylic acid, 6-chloro-2-methoxy-, methyl ester plays a crucial role in the synthesis of high-value specialty chemicals. Its versatility and reactivity contribute to the development of advanced materials and compounds used in various industries, including pharmaceuticals, fragrances, and flavorings.

Upstream product

• 124-41-4 sodium methylate 
• 65515-28-8 methyl 2,6-dichloronicotinate 
• 67-56-1 methanol 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 65515-33-5 6-chloro-2-methoxypyridine-3-carboxylic acid 
• 58584-86-4 ethyl 2,6-dichloronicotinate 

Downstream Products

• 680208-55-3 2-methoxy-6-(4-methoxy-benzylamino)-nicotinic acid methyl ester 
• 149539-81-1 methyl 6-amino-2-methoxypyridine-3-carboxylate 
• 680208-62-2 6-methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 680208-61-1 6-methoxy-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 1246765-51-4 methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-54-7 (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid 
• 1246765-52-5 (R)-methyl 6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinate 
• 1246765-27-4 methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate 

Relevant academic research and scientific papers

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

With the successful clinical application of anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) monoclonal antibodies (mAb), targeting the PD-1/PD-L1 interaction has become a promising method for the discovery of cancer therapy. Due to the inherent limitations of antibodies, it is necessary to search for small-molecule inhibitors against the PD-1/PD-L1 axis. We report the design, synthesis, and evaluation in vitro and in vivo of a series of novel biphenyl pyridines as the inhibitors of PD-1/PD-L1. 2-(((2-Methoxy-6-(2-methyl-[1,1′-biphenyl]-3-yl)pyridin-3-yl)methyl)amino)ethan-1-ol (24) was found to inhibit the PD-1/PD-L1 interaction with an IC50 value of 3.8 ± 0.3 nM and enhance the killing activity of tumor cells by immune cells. Compound 24 displays great pharmacokinetics (oral bioavailability of 22%) and significant in vivo antitumor activity in a CT26 mouse model. Flow cytometry and immunohistochemistry data indicated that compound 24 activates the immune activity in tumors. These results suggest that compound 24 is a promising small-molecule inhibitor against the PD-1/PD-L1 axis and merits further development.

Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1-Bak-BH3 Protein-Protein Interaction with 2,6-Di-Substituted Nicotinates

The disruption of aberrant protein-protein interactions (PPIs) with synthetic agents remains a challenging goal in contemporary medicinal chemistry but some progress has been made. One such dysregulated PPI is that between the anti-apoptotic Bcl-2 proteins, including myeloid cell leukemia-1 (Mcl-1), and the α-helical Bcl-2 homology-3 (BH3) domains of its pro-apoptotic counterparts, such as Bak. Herein, we describe the discovery of small-molecule inhibitors of the Mcl-1 oncoprotein based on a novel chemotype. Particularly, re-engineering of our α-helix mimetic JY-1-106 into 2,6-di-substituted nicotinates afforded inhibitors of comparable potencies but with significantly decreased molecular weights. The most potent inhibitor 2-(benzyloxy)-6-(4-chloro-3,5-dimethylphenoxy)nicotinic acid (1 r: Ki=2.90 μm) likely binds in the p2 pocket of Mcl-1 and engages R263 in a salt bridge through its carboxylic acid, as supported by 2D 1H-15N HSQC NMR data. Significantly, inhibitors were easily accessed in just four steps, which will facilitate future optimization efforts. 2,6-Di-substituted nicotinates inhibit the myeloid cell leukemia-1 (Mcl-1) oncoprotein with potencies in the single-digit micromolar range, as determined by a fluorescence polarization competition assay. Direct binding to Mcl-1 was confirmed by 2D 1H-15N HSQC NMR spectroscopy. Inspired by a fragment of a previously reported α-helix mimetic, the small-molecules reported herein are more druglike and, owing to greater synthetic accessibility, future optimization is expected to be elementary.

Substituted biphenyl compound as well as preparation method, application and pharmaceutical composition thereof

The invention discloses an immune checkpoint inhibitor substituted biphenyl compound capable of blocking a PD-1/PD-L1 signal path as well as a preparation method, application and a pharmaceutical composition of the immune checkpoint inhibitor substituted

PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as ΤΒΚ/ΙΚΚε inhibitors.

PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted indole compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, adisease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Synthesis and cross coupling of a highly substituted 2-pyridylboronate: Application to the large scale synthesis of a mineralocorticoid antagonist

The large scale synthesis of functionalized 2-pyridylboronate 8 and optimization of its Suzuki-Miyaura coupling to chloropyrazoline (R)-7 to provide a scalable synthesis of mineralocorticoid antagonist (R)-1 is described.

First synthesis of methyl 2-amino-6-methoxynicotinate using a combination of microwave and flow reaction technologies

The synthesis of methyl 2-amino-6-methoxynicotinate, a valuable building block for the preparation of fused 2-pyridones, is reported. The optimized synthesis includes sequential microwave-induced regioselective 6-methoxylation, esterification, followed by microwave-induced reaction with p- methoxybenzylamine, and final deprotection under flow reaction hydrogenation conditions. Two key steps in the reported synthesis are a microwave-induced methoxylation and a microfluidic hydrogenation that afford improved regioselectivity and purity profile of the reaction products. Georg Thieme Verlag Stuttgart.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

PIPERIDINE DERIVATIVES OR SALTS THEREOF

[Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).